Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

Exclusion Criteria

• •Patient has received prior treatment with Gemzar.
• •Patient has received any other investigational agents within 28 days of the first day of study drug dosing.
• •Patient is \< 5 years free of another primary malignancy except: if the other primary malignancy is neither currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
• •Patient with Grade III/IV cardiac problems as defined but the New York Heart Association Criteria.
• •Patients who are pregnant or breast-feeding.
• •Patient has a severe and/or uncontrolled medical disease (i,e. uncontrolled diabetes, uncontrolled chronic renal disease, or active uncontrolled infection).
• •Patient has a known untreated or progressive brain metastasis.
• •Patient has known chronic liver diseases (i.e. chronic active hepatitis, and cirrhosis.
• •Patient has a known diagnosis of human immunodeficiency virus (HIV infection ).
• •Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry, unless the disease is rapidly progressing..
• •Patient previously received radiotherapy to greater than or equal to 25% of the bone marrow.
• •Patient had a major surgery within 2 weeks prior to study entry.
• •Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.